Clinical Trial Update: Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating dual-target BCMA-CD19 CAR-T cell therapy for relapsed or refractory multiple myeloma with extramedullary infiltration is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Dual-target BCMA-CD19 CAR-T cell therapy (BCMA-CD19 CAR-T cells)

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 | Status: RECRUITING